Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
METfect-CNS
- Development stage
- Preclinical
- Lead developer
- Nanomerics
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
**METfect-CNS** is a preclinical Nanomerics non-viral, intranasal gene-delivery program for CNS neurodegeneration. The program uses Nanomerics' Molecular Envelope Technology nanoparticle platform to deliver siRNA and plasmid DNA through a nose-to-brain route, with the aim of modulating gene expression in the central nervous system while bypassing the blood-brain barrier. Specific therapeutic nucleic-acid sequences and molecular targets have not been publicly disclosed. ([nanomerics.com](https://www.nanomerics.com/post/nanomerics-reports-last-volunteer-visit-in-the-oc134-sunlight-trial-the-sunlight-trial-met-its-prim))
- Other names
- Naltos Nasal Gene Powder
02
Targets
DNA
Beyond the preview
Go deeper on METfect-CNS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on METfect-CNS.